October 10, 2025Annals of HematologyOpen Access

Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study

View Full Paper

Ask AI

Bookmark

Authors

XLXianghui LiuXiangtan University XXXin XiaShanghai Jiao Tong University LBLingyun BianShanghai Jiao Tong University

Discussion

Member takes

Implication

Prospective study shows mesenchymal stem cells enhance overall survival in patients with CMV pneumonia, suggesting potential benefits as adjuvant therapy.

Key Points

The MSC treatment group showed a significant increase in overall survival at 74%, as compared to 50% in the non-MSC group.
While the cure rates differed (79% MSC vs. 63% non-MSC), the difference was not statistically significant, indicating further investigation is needed.
This prospective study monitored 43 patients over six years post-allo-HSCT, emphasizing the urgent need for more research on MSC effectiveness.
Despite improved overall survival, the time to cure did not show a significant difference, pointing to complexities in treatment outcomes.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68e92b74531184d53775e2e4 https://doi.org/10.1007/s00277-025-06684-5

View Full Paper

Ask AI

Bookmark

Implication

Prospective study shows mesenchymal stem cells enhance overall survival in patients with CMV pneumonia, suggesting potential benefits as adjuvant therapy.

Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider